Brain cancer drug combo for kids with BRAF mutations
Part of Cancer clinical trials.
This trial tests a combination of targeted therapy (dabrafenib and trametinib) and immunotherapy (nivolumab) for children and young adults with certain BRAF gene changes in their glioma. It aims to see if this drug combination can shrink tumors or stop them from growing.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be between 1 and 26 years old.
- You must have a glioma (a type of brain tumor) with a specific BRAF gene change (either a fusion called KIAA1549-BRAF or a BRAF V600 mutation).
- You need to have had at least one prior treatment for your tumor, and it must have come back or not responded to that treatment.
- You must be generally well enough to be active (Karnofsky or Lansky score over 50).
- You must have adequate organ and bone marrow function.
- If you have a certain type of low-grade glioma, you must have already tried a BRAF or MEK inhibitor before.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests two targeted drugs (dabrafenib and trametinib) for children and young adults with a specific type of low-grade brain tumor that has a BRAF V600 mutation. The drugs work by blocking signals that help the tumor grow.
This Phase 2 study tests tovorafenib, a targeted cancer medicine, in children and young adults whose tumors have specific BRAF or RAF changes. It is for cancers that have come back or grown despite previous treatment, with measurable signs on scans.
This trial tests a new targeted medicine (FCN-159) against standard chemotherapy for children with slow-growing brain or nervous system tumors that have a specific genetic change (BRAF alteration). The goal is to see if the new pill works better at shrinking or controlling the tumor.
This trial is testing a combination of two drugs, vinblastine and tovorafenib, for children and young adults (up to age 25) whose low-grade glioma has come back or worsened after prior treatment. It is for people whose tumor has a specific change in a gene called BRAF or CRAF.
This trial tests a targeted drug, binimetinib, for people with low-grade glioma (a type of brain tumor) or pancreatic cancer that has a specific genetic change called a BRAF fusion. The drug aims to block signals that help these tumors grow.
This trial tests a drug called tovorafenib for children and young adults with certain types of brain tumors that have specific genetic changes. It is aimed at helping people who have just finished radiation therapy.
Hear when a new Low-grade Glioma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.